AR119974A1 - Composición radiofarmacéutica concentrada, estable - Google Patents
Composición radiofarmacéutica concentrada, estableInfo
- Publication number
- AR119974A1 AR119974A1 ARP200102561A ARP200102561A AR119974A1 AR 119974 A1 AR119974 A1 AR 119974A1 AR P200102561 A ARP200102561 A AR P200102561A AR P200102561 A ARP200102561 A AR P200102561A AR 119974 A1 AR119974 A1 AR 119974A1
- Authority
- AR
- Argentina
- Prior art keywords
- radionuclide
- salts
- optionally
- pharmaceutical composition
- complex formed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19197607 | 2019-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119974A1 true AR119974A1 (es) | 2022-01-26 |
Family
ID=67981980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102561A AR119974A1 (es) | 2019-09-16 | 2020-09-15 | Composición radiofarmacéutica concentrada, estable |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220401593A1 (enExample) |
| EP (1) | EP4031193A1 (enExample) |
| JP (2) | JP7762648B2 (enExample) |
| KR (1) | KR20220063218A (enExample) |
| CN (1) | CN114728088A (enExample) |
| AR (1) | AR119974A1 (enExample) |
| AU (1) | AU2020349002B2 (enExample) |
| CA (1) | CA3154302A1 (enExample) |
| IL (1) | IL291315A (enExample) |
| TW (1) | TW202123976A (enExample) |
| WO (1) | WO2021052960A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250032652A1 (en) * | 2021-11-30 | 2025-01-30 | Nihon Medi-Physics Co., Ltd. | Stabilized radiopharmaceutical composition |
| CN114404618A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其用途 |
| CN114404619A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| CN116920129A (zh) * | 2022-04-02 | 2023-10-24 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| EP4661919A1 (en) | 2023-02-08 | 2025-12-17 | Novartis AG | Methods for treating glioblastoma |
| JP2026506981A (ja) | 2023-02-23 | 2026-02-27 | ノバルティス アーゲー | 乳癌を治療するための方法 |
| WO2025058000A1 (ja) | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
| WO2025126151A1 (en) | 2023-12-15 | 2025-06-19 | Novartis Ag | Methods for treating breast cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177216A1 (en) * | 2003-07-24 | 2012-01-30 | Bracco Imaging Spa | Stable radiopharmaceutical compositions and methods for their preparation |
| WO2008009444A1 (en) | 2006-07-19 | 2008-01-24 | Van Dulmen, Adrianus, A. | Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide |
| LT2900279T (lt) | 2012-09-25 | 2019-11-11 | Advanced Accelerator Applications Usa Inc | Grpr antagonistai, skirti grpr atžvilgiu teigiamo vėžio nustatymui, diagnozavimui ir gydymui |
-
2020
- 2020-09-15 JP JP2022516404A patent/JP7762648B2/ja active Active
- 2020-09-15 WO PCT/EP2020/075767 patent/WO2021052960A1/en not_active Ceased
- 2020-09-15 US US17/753,762 patent/US20220401593A1/en active Pending
- 2020-09-15 AR ARP200102561A patent/AR119974A1/es unknown
- 2020-09-15 EP EP20768373.1A patent/EP4031193A1/en active Pending
- 2020-09-15 KR KR1020227012069A patent/KR20220063218A/ko active Pending
- 2020-09-15 CA CA3154302A patent/CA3154302A1/en active Pending
- 2020-09-15 CN CN202080079709.9A patent/CN114728088A/zh active Pending
- 2020-09-15 TW TW109131644A patent/TW202123976A/zh unknown
- 2020-09-15 AU AU2020349002A patent/AU2020349002B2/en active Active
-
2022
- 2022-03-13 IL IL291315A patent/IL291315A/en unknown
-
2025
- 2025-06-11 US US19/234,864 patent/US20250332301A1/en active Pending
- 2025-10-20 JP JP2025176508A patent/JP2026031934A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202123976A (zh) | 2021-07-01 |
| KR20220063218A (ko) | 2022-05-17 |
| US20220401593A1 (en) | 2022-12-22 |
| JP2026031934A (ja) | 2026-02-25 |
| CA3154302A1 (en) | 2021-03-25 |
| IL291315A (en) | 2022-05-01 |
| EP4031193A1 (en) | 2022-07-27 |
| JP2022548875A (ja) | 2022-11-22 |
| JP7762648B2 (ja) | 2025-10-30 |
| CN114728088A (zh) | 2022-07-08 |
| WO2021052960A1 (en) | 2021-03-25 |
| AU2020349002B2 (en) | 2024-05-02 |
| AU2020349002A1 (en) | 2022-04-28 |
| US20250332301A1 (en) | 2025-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119655A1 (es) | Soluciones de complejos de radionúclidos estables y concentradas | |
| US20170224789A1 (en) | Stable injectable composition of bivalirudin and process for its preparation | |
| ECSP088175A (es) | Liberación sostenida de agentes antiinfecciosos | |
| PE20241305A1 (es) | Analogos de amilina | |
| GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
| AR084663A1 (es) | Preparados liofilizados de inhibidores de proteasomas | |
| BR112015012460B1 (pt) | Formulação estabilizada de pemetrexede | |
| AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
| PE20220377A1 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| PT2777689E (pt) | Nova composição farmacêutica para o tratamento de infeções fúngicas | |
| JP2009521473A5 (enExample) | ||
| AR029456A1 (es) | Forma triturada | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| MX2019007239A (es) | Nueva formulacion que comprende un derivado de bencimidazol. | |
| ES479423A1 (es) | Procedimiento para la preparacion de 2-2-tenoiltio-propio- nil-glicina. | |
| US20210196673A1 (en) | Compositions and methods for treating and preventing respiratory viral infections using green tree extract | |
| KR20210075968A (ko) | 구강 점막염을 치료하기 위한 방법 및 조성물 | |
| AR124036A1 (es) | Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición | |
| ES2312921T3 (es) | Disolucion acuosa concentrada de ambroxol. | |
| EP2804597B1 (en) | Aqueous paracetamol composition for injection | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| US20200297849A1 (en) | Stable liquid pharmaceutical compositions comprising bendamustine | |
| PE20190168A1 (es) | Complejos radiofarmaceuticos | |
| EP3866773B1 (en) | Carbon monoxide prodrugs for the treatment of medical disorders | |
| KR20160115827A (ko) | 인돌 화합물을 포함하는 제제 및 이의 제조 방법 |